Background: Since primary membranous nephropathy is a heterogeneous disease with variable outcomes and multiple possible therapeutic approaches, all 13 Nephrology Units of the Italian region Emilia Romagna decided to analyze their experience in the management of this challenging glomerular disease. Methods: We retrospectively studied 205 consecutive adult patients affected by biopsy-proven primary membranous nephropathy, recruited from January 2010 through December 2017. The primary outcome was patient and renal survival. The secondary outcome was the rate of complete remission and partial remission of proteinuria. Relapse incidence, treatment patterns and adverse events were also assessed. Results: Median (IQR) follow-up was 36 (24-60) months. Overall patient and renal survival were 87.4% after 5 years. At the end of follow-up, 83 patients (40%) had complete remission and 72 patients (35%) had partial remission. Among responders, less than a quarter (23%) relapsed. Most patients (83%) underwent immunosuppressive therapy within 6 months of biopsy. A cyclic regimen of corticosteroid and cytotoxic agents was the most commonly used treatment schedule (63%), followed by rituximab (28%). Multivariable analysis showed that the cyclic regimen significantly correlates with complete remission (odds ratio 0.26; 95% CI 0.08-0.79) when compared to rituximab (p < 0.05). Conclusions: In our large study, both short- and long-term outcomes were positive and consistent with those published in the literature. Our data suggest that the use of immunosuppressive therapy within the first 6 months after biopsy appears to be a winning strategy, and that the cyclic regimen also warrants a prominent role in primary membranous nephropathy treatment, since definitive proof of rituximab superiority is lacking.

Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up / Albertazzi, V.; Fontana, F.; Giberti, S.; Aiello, V.; Battistoni, S.; Catapano, F.; Graziani, R.; Cimino, S.; Scichilone, L.; Forcellini, S.; De Fabritiis, M.; Sara, S.; Delsante, M.; Fiaccadori, E.; Mosconi, G.; Storari, A.; Mandreoli, M.; Bonucchi, D.; Buscaroli, A.; Mancini, E.; Rigotti, A.; La Manna, G.; Gregorini, M.; Donati, G.; Cappelli, G.; Scarpioni, R.. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - (2023), pp. 1-12. [10.1007/s40620-023-01803-9]

Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up

Albertazzi V.;Fontana F.;Aiello V.;Graziani R.;Scichilone L.;Donati G.;Cappelli G.;
2023

Abstract

Background: Since primary membranous nephropathy is a heterogeneous disease with variable outcomes and multiple possible therapeutic approaches, all 13 Nephrology Units of the Italian region Emilia Romagna decided to analyze their experience in the management of this challenging glomerular disease. Methods: We retrospectively studied 205 consecutive adult patients affected by biopsy-proven primary membranous nephropathy, recruited from January 2010 through December 2017. The primary outcome was patient and renal survival. The secondary outcome was the rate of complete remission and partial remission of proteinuria. Relapse incidence, treatment patterns and adverse events were also assessed. Results: Median (IQR) follow-up was 36 (24-60) months. Overall patient and renal survival were 87.4% after 5 years. At the end of follow-up, 83 patients (40%) had complete remission and 72 patients (35%) had partial remission. Among responders, less than a quarter (23%) relapsed. Most patients (83%) underwent immunosuppressive therapy within 6 months of biopsy. A cyclic regimen of corticosteroid and cytotoxic agents was the most commonly used treatment schedule (63%), followed by rituximab (28%). Multivariable analysis showed that the cyclic regimen significantly correlates with complete remission (odds ratio 0.26; 95% CI 0.08-0.79) when compared to rituximab (p < 0.05). Conclusions: In our large study, both short- and long-term outcomes were positive and consistent with those published in the literature. Our data suggest that the use of immunosuppressive therapy within the first 6 months after biopsy appears to be a winning strategy, and that the cyclic regimen also warrants a prominent role in primary membranous nephropathy treatment, since definitive proof of rituximab superiority is lacking.
2023
1
12
Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up / Albertazzi, V.; Fontana, F.; Giberti, S.; Aiello, V.; Battistoni, S.; Catapano, F.; Graziani, R.; Cimino, S.; Scichilone, L.; Forcellini, S.; De Fabritiis, M.; Sara, S.; Delsante, M.; Fiaccadori, E.; Mosconi, G.; Storari, A.; Mandreoli, M.; Bonucchi, D.; Buscaroli, A.; Mancini, E.; Rigotti, A.; La Manna, G.; Gregorini, M.; Donati, G.; Cappelli, G.; Scarpioni, R.. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - (2023), pp. 1-12. [10.1007/s40620-023-01803-9]
Albertazzi, V.; Fontana, F.; Giberti, S.; Aiello, V.; Battistoni, S.; Catapano, F.; Graziani, R.; Cimino, S.; Scichilone, L.; Forcellini, S.; De Fabritiis, M.; Sara, S.; Delsante, M.; Fiaccadori, E.; Mosconi, G.; Storari, A.; Mandreoli, M.; Bonucchi, D.; Buscaroli, A.; Mancini, E.; Rigotti, A.; La Manna, G.; Gregorini, M.; Donati, G.; Cappelli, G.; Scarpioni, R.
File in questo prodotto:
File Dimensione Formato  
Albertazzi J Nephrol 2023.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1328146
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact